Lonza wins exclusive 5-year manufacturing contract from Index ventures

- Last updated on GMT

Lonza wins exclusive 5-year manufacturing contract from Index ventures

Related tags: Investment, Lonza

Lonza has been selected to develop and manufacture all biologics for the biotech companies in capital investment firm Index Ventures' portfolio.

The venture firm announced it had entered into an exclusive agreement with the Switzerland-headquartered contract manufacturing organization (CMO) Lonza this morning. The five-year deal will see Lonza fulfill all process development and GMP production of biological products in the portfolio of companies where Index is the major investor.

According to Dr. Stephan Kutzer, COO Lonza Pharma & Biotech, “this multi-product agreement demonstrates Lonza's ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.”

Kevin Johnson, Partner at Index Ventures said Lonza had been selected in part due to previous antibody products he had worked on in the last 20 years and this deal will enable Index’ asset-centric portfolio companies “to benefit as though they were much larger organisations.”

According to its website​, Index has 31 mostly start-up and small biotech Life Science companies in its portfolio. 

Related news

Show more

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more